Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Weyerhaeuser Company Common Stock (WY) Price & Performance

10X Genomics IncTrade
Weyerhaeuser Company Common StockTrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Weyerhaeuser Company Common Stock — how do they compare? 10X Genomics Inc trades at $72.15 (market cap $9.35B), while Weyerhaeuser Company Common Stock trades at $19.16 (market cap $13.67B). The key difference: Weyerhaeuser Company Common Stock is the larger of the two by market cap, and Weyerhaeuser Company Common Stock pays a 4.43% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

TXGWY
Market Cap
$9.35B$13.67B
Volume
4,039,4496,820,453
Sector
HealthReal Estate
52-Week High
$97.74$27.10
52-Week Low
$11.83$18.47
Typical Hold Time
91 Days—
Enterprise Value
$8.88B$18.59B
Dividend Yield
—4.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.

The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.

Weyerhaeuser Company Common Stock

Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.

Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TXG
17% Buy83% Sell
Avg holding period · 91 Days
WY

No sentiment data available yet.

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →

About Weyerhaeuser Company Common Stock

Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.

Read more on WY →